Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kínisi is a multi-ingredient nutraceutical supplement developed and marketed by the Mexican pharmaceutical company Industria Farmacéutica Andrómaco. Formulated as oral capsules, it is specifically designed to support joint health and preservation by providing essential nutrients. The product contains a combination of ascorbic acid (vitamin C), hyaluronic acid, collagen, and pomegranate extract. These ingredients are intended to support the structural integrity of joint cartilage and provide antioxidant protection against oxidative stress in joint tissues. Kínisi is also marketed under the brand name Fluidart and represents a dietary supplement approach to joint maintenance rather than a traditional pharmaceutical intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kínisi.